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Abstract
The first gene-edited human babies were born in China in late 2018, but no new
legislation has been enacted despite widespread outrage. There is a pressing societal
need to address the moral and ethical issues associated with germline gene editing
before more cases occur. A temporary worldwide moratorium on reproductive germline
gene editing should be instituted immediately until such a time as an International Gene
Editing Agency is established to develop an enforceable global regulatory framework
with broad public engagement. This will, in turn, give us the opportunity to rethink
the ethics of heritability in a post-gene editing world.
Introduction
On 25th November 2018, Dr He Jiankui, an as-
sociate professor at the Southern University of
Science and Technology in Shenzhen, China, re-
leased a series of Youtube videos in which he
announced the birth of the first gene-edited hu-
man babies [1]. Unlike any experiment that came
before, Dr He edited the genomes of two single-
cell female embryos with the aim to edit every
cell in the body. Since this includes the egg and
sperm cells, known as germline cells, these edits
may be passed down to any future descendants
these babies eventually have. In contrast, editing
of adult (somatic) cells cannot be passed on to
future generations and is therefore isolated in the
individual patient [2].
While I was immediately captivated, I was hesi-
tant to publish a response. Surely this was the
stimulus that policymakers needed to finally reg-
ulate emerging gene editing technologies, so any
policy recommendations that I could make would
be immediately superseded by an actual proposal.
Instead, the worst has come to pass: the news
cycle moved on, and few remain talking about
the little girls who made history.
To perform this experiment, Dr He used CRISPR,
a technology for cutting DNA at precise, customis-
able locations. While this article focuses on the
ethics rather than the science of CRISPR, those
unfamiliar with how it works may find a review
article about its history and technical specifics
helpful [3]. Full details of Dr He’s work have not
been published, so unfortunately many scientific
questions remain unanswered, such as whether
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both copies of the genome were edited in every
cell as claimed, but the Chinese government has
confirmed that the editing did take place [4].
After presenting selected data at the Second Inter-
national Summit on Human Genome Editing just
three days following his announcement, Dr He
was met with nearly unanimous criticism by fel-
low scientists [5, 6]. The next day it was reported
by Chinese state media that the Chinese govern-
ment had suspended his lab’s research [7], and
his lab website was taken offline. Dr He himself
has not spoken publicly since the summit, and
he has since been fired by his university and was
sentenced to three years in prison for performing
‘illegal medical practices’ [8].
In Dr He’s defence, it was not at all initially
obvious that what he did was illegal. Unlike
in the UK, where the Human Fertilisation and
Embryology Authority (HFEA) explicitly bans
germline editing [9], there was no law or regu-
lation specifically banning it in China. Instead,
the ‘Technical Norms on Human Assisted Repro-
ductive Technologies’ published by the Chinese
Ministry of Health in 2003 states ‘the use of ge-
netically manipulated human [. . . ] embryos for
the purpose of reproduction is prohibited’ [10].
While this should have dissuaded Dr He, such
technical norms are generally unenforceable with-
out being authorised by law, so it was not until
this case became a sensation that it was clear that
flouting the norm would actually be punishable.
Meanwhile, many countries including the United
States have no laws regulating this new technol-
ogy (although the US has banned federal funds
from being used for germline editing research) [9].
It is unknown where germline gene editing re-
search will go from here. On one hand, Dr He
shows us that a small team of scientists is ca-
pable of performing a germline gene edit on a
human embryo resulting in a live birth. Over the
past year, Dr Denis Rebrikov at the Pirogov Med-
ical University in Moscow has also been vocal
about performing similar edits on human em-
bryos—although he claims he will not implant
them until he gains regulatory approval [11]. On
the other hand, the vilification that Dr He has
received will hopefully deter the majority of sci-
entists from repeating his work, and, at present,
the expertise and resources required to perform
this feat are a sufficient hurdle to prevent non-
scientists from trying to replicate it. However,
there is a real possibility that research will be
done in secret or that future advancements will
remove technical barriers to entry, so the time is
ripe to act on a global scale to regulate germline
gene editing.
Available Policy Pathways
We are at a crossroads with four paths forward:
we could deregulate germline gene editing by ei-
ther repealing or choosing not to enforce existing
regulations, we could ban it entirely, we could
fracture into a patchwork of national regulations
with no global cohesion, or we could work to de-
termine a single path forward as a species. While
it is the most difficult, I see the final option as the
only viable scenario in the long term. However,
there are still many traps that must be avoided,
and I will seek to both justify this belief and
outline what it might take to bring it about.
At the dawn of the modern genetic era, the
1975 Asilomar Conference on Recombinant DNA
Molecules recognised that unrestricted manipula-
tion of DNA in the lab presents many unknown
risks, and, in the absence of laws, scientists re-
solved to set restrictions on themselves [12]. For
over forty years, this voluntary self-regulation has
been the norm for much of biotechnology, espe-
cially in the US, but this should only be seen as
a stopgap and not a permanent solution.
There are numerous technical risks for both in-
dividuals and the species should germline gene
editing go ahead unchecked: CRISPR is rela-
tively inefficient, often successfully editing only
a small percent of cells, and it can also cause
off-target mutations, where it cuts DNA at the
wrong location, which could cause cancer or any
number of genetic diseases [13]. However, the
field of gene editing moves fast. New research
is published daily in this highly competitive and
lucrative field, such as one study detailing how
to design CRISPR edits to reduce the chance of
off-target effects [14] and a recent clinical trial
demonstrating the safety and feasibility of using
CRISPR-edited immune cells to target cancer
[15].
There is good reason to be hopeful that the techni-
cal problems with CRISPR will be fixed, but the
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ethical concerns are much more complex. There
is no clear line between eliminating a genetic
disease and enhancing a desired trait; the same
gene that causes muscular dystrophy when lost
could increase physical strength if amplified [16].
Additionally, the US allows patenting of both
the editing technology and the edits themselves,
which grants the companies developing them im-
mense power over their implementation. One
needs only to look at the price of prescription
drugs in a for-profit market to see that access to
any gene editing technology developed by private
companies would be restricted to only the wealth-
iest. A report published by Goldman Sachs last
year states ‘given the possible one-time curative
nature of gene therapy, we believe price tags of
$1mn+ [per patient] are likely’ [17]. Such a price
would be inaccessible for the vast majority of pa-
tients and would stretch social healthcare systems
beyond many of their capacities.
Moreover, tampering with the natural human
gene pool is inherently a major risk in the long
term. Differences in environments and cultural
ideals (e.g., beauty standards) could lead to the
promulgation of different traits in different pop-
ulations far faster and more effectively than the
existing mode of sexual selection, which could
fracture humanity into various subspecies over
time or put unedited individuals at a social disad-
vantage. Additionally, homogenization of human
genetics could reduce diversity and resistance to
infectious diseases. Similarly, we know that plant-
ing only one variety of crop makes a field more
prone to disease than planting crops with more
genetic variation [18]. The risks of germline edit-
ing are simply too great to allow a laissez-faire
approach.
Technological advancements cannot inform our
morality, and likewise CRISPR cannot tell us
whether we want to direct human evolution or
how. It is my personal belief that we are simply
not ready as a society or a species for germline
gene editing, and if or when we do allow it, it
should be a conscious collective decision after
suitable scrutiny, education, and debate rather
than an individual deciding to pursue it simply
because they can.
However, the potential for misuse does not make
gene editing itself immoral. CRISPR is an in-
credibly powerful research tool which has rev-
olutionised biology, allowing scientists unprece-
dented ability to manipulate the genetics of cell
and animal models. This has opened doors for
the discovery of novel pharmaceuticals and gene
interactions via whole genome CRISPR screens,
and new variants of CRISPR can, among other
things, transiently affect gene expression without
permanently altering the DNA [3].
Applications in adult (somatic) cells also promise
to translate CRISPR to human health in untold
ways. From curing chronic diseases to eliminat-
ing mutated cancer cells with pinpoint accuracy,
several such treatments are starting to make their
way to patients and showing promising results
[15, 19]. No matter one’s objections to germline
editing, it is difficult to justify accepting the sta-
tus quo of congenital diseases when so many could
be cured in the individual by somatic gene ther-
apies or prevented entirely by existing genetic
counselling practices coupled with limited and
precise germline edits. In order to reap these ben-
efits, fundamental research and somatic clinical
applications should be enthusiastically supported,
and a complete ban on gene editing or even a
permanent ban on just germline editing should
not be pursued.
Our current situation, and the most likely sce-
nario for the near future, is that each country
will form its own policies to regulate gene edit-
ing as they have done with fertility treatments,
stem cell therapies, and other medical procedures
[20]. This has worked in the past and should
work for somatic gene editing, since treatments
are confined to the individual patient. However,
once a germline gene edit enters the gene pool,
the only way it can be removed is if none of
the carriers have children, or at least if none of
these children receive any edited chromosomes.
Should any country allow widespread germline
gene editing, nothing short of completely clos-
ing them off from the rest of the world would
prevent comingling of edited and unedited pop-
ulations. A hypothetical genetic edit should not
deprive a person of basic human rights, so any
program of compulsory genotyping, labelling of
gene-edited individuals, or limiting of reproduc-
tive rights should be immediately rejected. And
even should such draconian measures be put in
place, they would be ineffective; every generation
acquires numerous new random mutations in their
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genomes which are afterwards indistinguishable
from most targeted edits. Therefore, a germline
editing ban—or even limits and regulations—in
a single country but not the world is effectively
meaningless.
Policy Recommendations
So, if a single path forward is the best option,
what should it be? Any policy must be both
global and enforceable to be effective; therefore,
a binding international treaty should be immedi-
ately pursued to:
1. impose a temporary, 5-year moratorium
on human germline gene editing, until
such time as
2. an International Gene Editing Agency
can be established and enact initial regu-
lations. This agency would also be em-
powered to act as a watchdog.
This approach may appear reminiscent of a failed
attempt in the early 2000’s to ban human cloning
via treaty, where a lack of real urgency and
vague technical language resulted instead in a
non-binding declaration [21]. A similar fate befell
a Convention on Human Rights and Biomedicine
proposed to the Council of Europe in the late
1990s [22], and both resulted in a patchwork of
national regulation. Instead, if it had been an-
nounced that human cloning was actively ongoing,
countries seeking a full ban would likely have com-
promised for some restrictions, and likewise had
the treaty included a sunset clause, it likely would
have placated the countries that were against a
full ban. UNESCO has also published declara-
tions on bioethics [23], but they too suffer from
unenforceability. Instead of adding enforcement
to the broad scope of UNESCO’s Constitution,
establishing an independent organisation will pro-
vide greater transparency, efficacy, and manoeu-
vrability.
The International Atomic Energy Agency serves
as a particularly useful model, as they are in-
vested with the power to issue standards and
perform inspections ensuring the safety of nu-
clear power and preventing the proliferation of nu-
clear weapons while also operating autonomously
from the UN. Although it would be significantly
more difficult to detect germline gene editing
than atomic bombs, independent audits of repro-
ductive therapy providers and research funding
portfolios would be widely effective, coupled with
public outreach to encourage reporting of rogue
actors. Additionally, China’s strong response to
Dr He’s work suggests that there is the political
will for individual states along with the UN to iso-
late and sanction those that refuse to subscribe
to the regulations in a manner comparable to
nations in violation of the Treaty on the Non-
Proliferation of Nuclear Weapons. In this way,
we may not prevent all cases of germline editing,
but we can prevent it from becoming mainstream
while also providing a mechanism to permit cer-
tain applications in the future.
This recommendation builds on previous calls for
a global gene editing observatory [24]. Jasanoff
and Hurlbut envision the establishment of new
institutions for careful deliberation across profes-
sional and national boundaries, but it is now
clear that there is an urgent need for action
while policymakers can come to terms with the
details—therefore, a temporary moratorium on
germline editing while the Agency is created. And
while their proposed observatory would be an
ideal model for determining the rules for CRISPR
moving forward, it lacks power and must be cou-
pled with a mechanism of enforcement—therefore,
the establishment of the proposed Agency.
In an apparent attempt to get out ahead of the
backlash, Dr He published a list of principles
for regulating human germline gene editing just
before his announcement [25], such as ‘only for
serious disease, never vanity,’ and ‘wealth should
not determine health.’ This article has since been
retracted by the journal, but it offers a glimpse
into the reasoning Dr He used to justify his work.
In fact, his recommendations would have been
useful if we lived in a world in which germline
gene editing was broadly accepted, but that is
simply not the case, and the risks of implemen-
tation on a global scale have not been properly
evaluated. Dr He clearly miscalculated how hos-
tile the response to his news would be, and as a
result these suggestions have been largely lost in
the noise.
I cannot say exactly what specific regulations
should be made, and neither is it any individual’s
place to dictate what these regulations should be.
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Instead, it is the responsibility of everyone in a so-
ciety to say what they want in order to determine
policy, via a concept coined by Jasanoff called
civic epistemology, or the ‘stylized, culturally-
specific ways in which publics expect the state’s
expertise, knowledge, and reasoning to be pro-
duced, tested, and put to use in decision making’
[20]. While the proposed Agency provides a ves-
sel for making and enforcing regulations, we must
decide together how to fill it. We therefore face
the enormous task of synthesising our various
culture-specific epistemologies into a single new
one as a species.
A Brave New World?
CRISPR technology fundamentally changes our
understanding of heritability and of what it means
to be human. Before, it was impossible to sepa-
rate the genome from the individual or to conceive
of a way to design or alter the genetic code of
one’s offspring. The entire concept of familial her-
itage is intimately connected to the assumption
that your genome is unique, inalienable, and, to
put it simply, yours to begin with. How, then,
can the ethics derived before gene editing carry
over? Instead, we should see the development
of germline gene editing as an opportunity to
re-examine how we conceive human evolution.
Genetic variation is necessary for evolution to
occur; we must then decide whether to end the
evolution of humanity by eliminating variation,
whether to allow it to proceed as the slow and
random process it has for the history of life, or
whether to accelerate it deliberately through ge-
netic intervention. As this is a monumental deci-
sion, it should not be made hastily and certainly
not by a privileged few. Instead, scientists must
seek to effectively communicate with and educate
everyone about the possibilities of gene editing as
they develop, and perhaps someday the proposed
Agency can be replaced with ongoing global refer-
enda with equal, universal suffrage to determine
our course forward.
Two years before Asilomar, science fiction writer
Robert A. Heinlein predicted a future of unin-
hibited genetic editing. When the protagonist
of the novel is cloned (and these clones geneti-
cally edited) without his knowledge, he reasons
‘You don’t own your genes—nobody does. Genes
belong to the race; they’re simply lent to the indi-
vidual for his-her lifetime’ [26]. Heinlein’s vision
should scare us, but there is perhaps some truth
to his reasoning. We should think of our genetics
as a Commons that we all share and all must pro-
tect, and rather than assigning different values
to certain genetic varieties as ‘good’ or ‘bad’, we
should realise that all DNA has the same value.
We may recognise that specific mutations which
lead to disease are detrimental, but even these do
not alter the moral worth of the DNA or of the
individual who is ‘borrowing’ it from the species.
Instead, it is the depth of the gene pool that is
our strength as a species, and in order to be good
stewards of the human genome, we must actively
restrain and refocus the use of this powerful tech-
nology in a manner that is democratic—and never
plutocratic or eugenic. We all have a share in
this, so we all deserve a say.
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